+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 75Years
All Genders
ID06417008

Study of HS-20117 and Aumolertinib to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer with EGFR Mutation

Led by Hansoh BioMedical R&D Company · Updated on 2025-08-01

1080

Participants Needed

2

Research Sites

208 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, effectiveness, how the body processes, and immune response to HS-20117 combined with Aumolertinib in adults with advanced non-squamous non-small cell lung cancer NSCLC that has specific EGFR mutations. This study is a Phase IbIII clinical trial involving participants with newly diagnosed, locally advanced or metastatic NSCLC who have not received prior treatment for this condition. The goal is to determine the recommended dose and confirm the benefits and safety of combining these two drugs compared to Aumolertinib alone. The study has two phases Phase Ib involves giving HS-20117 by intravenous infusion once during the first 28-day cycle and every two weeks in subsequent cycles, alongside daily oral doses of Aumolertinib at 110 mg. After safety and dose confirmation, Phase III will randomly assign participants to receive either the combination of HS-20117 and Aumolertinib or Aumolertinib alone, with all treatments continuing in 28-day cycles. Participants will undergo assessments including tumor imaging to measure response and progression, blood tests to study drug levels and immune reactions, and monitoring for side effects throughout treatment, which may last up to approximately 40 months. The study will track outcomes such as response rates, progression-free survival, overall survival, and adverse events. Safety follow-up will continue for at least 90 days after the final dose, and the total observation may extend to about 60 months.

CONDITIONS

Brief Title

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Research Team

J

Jialei Fu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here